Skip to main content

Advertisement

Table 5 Odds ratios of MetS at baseline and longitudinal status change in MetS for new onset of type 2 diabetes

From: Impact of longitudinal status change in metabolic syndrome defined by two different criteria on new onset of type 2 diabetes in a general Japanese population: the Tanno–Sobetsu Study

  MetS-INT MetS-JP
Model 1 Model 2a Model 1 Model 2b
MetS at baseline 3.46** (2.02–5.91) 1.49 (0.82–2.69) 5.15** (2.60–10.20) 3.45** (1.68–7.05)
  1. Model 1 adjusted for age, sex
  2. Model 2 Model 1 + FPG ≥100 mg/dl at baseline
  3. Model 3 Model 1 + FPG ≥110 mg/dl at baseline
  4. MetS-INT metabolic syndrome assessed by the interim criteria by 6 institutions, MetS-JP metabolic syndrome assessed by the Japanese criteria
  5. * p < 0.05
  6. ** p < 0.01
  Model 1 Model 2a Model 1 Model 2b
Non-MetS to non-MetS 1.00 1.00 1.00 1.00
Non-MetS to MetS 4.86** (2.44–9.70) 4.16** (2.03–8.53) 4.28** (2.27–8.08) 4.11** (2.08–8.13)
MetS to non-MetS 4.97** (1.89–13.07) 1.75 (0.63–4.89) 3.06 (0.95–9.87) 0.93 (0.25–3.48)
MetS to MetS 7.50** (3.67–15.33) 3.38** (1.57–7.25) 15.55** (6.71–36.07) 6.64** (2.46–17.89)
  1. Model 1 adjusted for age, sex
  2. Model 2 Model 1 + FPG ≥100 mg/dl at baseline
  3. Model 3 Model 1 + FPG ≥110 mg/dl at baseline
  4. MetS-INT metabolic syndrome assessed by the interim criteria by 6 institutions, MetS-JP metabolic syndrome assessed by the Japanese criteria
  5. * p < 0.05
  6. ** p < 0.01